专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

61. 发明申请

US20080132575A1 Formulations Of Suberoylanilide Hydroxamic Acid And Methods For Producing Same 有权
标题翻译：苯乙酰苯胺羟肟酸的制剂及其制备方法
公开(公告)号：US20080132575A1
公开(公告)日：2008-06-05
申请号：US11663165
申请日：2006-05-16
申请人： Jeannie Chow Wong , Aaron S. Cote , Erik A. Dienemann , Kimberly Gallagher , Craig Ikeda , Justin Moser , Pavol Rajniak , Robert A. Reed , Cindy Starbuck , Hsien-Hsin Tung , Qingxi Wang , Benjamin Max Cohen , Vincent R. Capodanno , Brian Sell , Thomas A. Miller
发明人： Jeannie Chow Wong , Aaron S. Cote , Erik A. Dienemann , Kimberly Gallagher , Craig Ikeda , Justin Moser , Pavol Rajniak , Robert A. Reed , Cindy Starbuck , Hsien-Hsin Tung , Qingxi Wang , Benjamin Max Cohen , Vincent R. Capodanno , Brian Sell , Thomas A. Miller
IPC分类号： A61K31/185 , A61P35/00
CPC分类号： A61K31/19
摘要： The present invention provides a pharmaceutical composition or crystalline composition with a specific dissolution profile, which comprises suberoylanilide hydroxamic acid or a pharmaceutically acceptable salt or hydrate thereof as an active ingredient. The present invention provides a process of producing said crystalline composition or pharmaceutical composition. The present invention also provides compositions with a specific particle size distribution.
摘要翻译：本发明提供具有特定溶出曲线的药物组合物或结晶组合物，其包含辛二酰苯胺异羟肟酸或其药学上可接受的盐或水合物作为活性成分。本发明提供了制备所述结晶组合物或药物组合物的方法。本发明还提供具有特定粒度分布的组合物。

62. 发明授权

US07148257B2 Methods of treating mesothelioma with suberoylanilide hydroxamic acid 有权
标题翻译：用辛二酰苯胺异羟肟酸治疗间皮瘤的方法
公开(公告)号：US07148257B2
公开(公告)日：2006-12-12
申请号：US10650025
申请日：2003-08-26
申请人： Nicholas G. Bacopoulos , Judy H. Chiao , Thomas A. Miller , Carolyn M. Paradise , Victoria M. Richon
发明人： Nicholas G. Bacopoulos , Judy H. Chiao , Thomas A. Miller , Carolyn M. Paradise , Victoria M. Richon
IPC分类号： A61K31/165
CPC分类号： A61K9/4866 , A61K9/0019 , A61K9/1652 , A61K31/13 , A61K31/165 , A61K31/19 , A61K31/44 , A61K47/12 , A61K47/38
摘要： Methods for treating mesothelioma comprising administering the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) are disclosed.
摘要翻译：公开了用于治疗间皮瘤的方法，包括给予组蛋白脱乙酰酶抑制剂辛二酰苯胺异羟肟酸（SAHA）。

63. 发明授权

US5865232A Method and apparatus for cutting veneer sheets from a tapered flitch 失效
标题翻译：从锥形薄片切割单板的方法和装置
公开(公告)号：US5865232A
公开(公告)日：1999-02-02
申请号：US813669
申请日：1997-03-07
申请人： Thomas A. Miller , Darrel C. Pinkston
发明人： Thomas A. Miller , Darrel C. Pinkston
IPC分类号： B25B5/00 , B25B5/08 , B25B5/14 , B27L5/00 , B27L5/04 , B27L5/06 , B27C1/00 , B27M1/02
CPC分类号： B27L5/04 , B25B5/003 , B25B5/087 , B25B5/147 , B27L5/004 , B27L5/06
摘要： A novel method and apparatus for cutting veneer sheets from a tapered flitch (one-half of a veneer log which has been sawn in half longitudinally) that places the veneer producing face of a tapered flitch in a stable, parallel relationship with the veneer slicing knife, thereby allowing full utilization of the natural taper of a veneer log.
摘要翻译：一种新颖的方法和装置，用于从锥形薄片（已经锯切成两半纵向的薄板原木的一半）切割单板，其将单板生产锥形薄片的表面与单板切片刀保持稳定的平行关系，从而允许充分利用单板日志的天然锥度。

64. 发明授权

US5747057A Sustained release pyriproxifen compositions for parasite control 失效
标题翻译：用于寄生虫控制的持续释放的艾曲瑞芬组合物
公开(公告)号：US5747057A
公开(公告)日：1998-05-05
申请号：US626001
申请日：1996-04-01
申请人： Thomas A. Miller
发明人： Thomas A. Miller
IPC分类号： A01K13/00 , A01K27/00 , A01N37/52 , A01N43/40 , A01N47/12 , A01N53/02 , A61K9/00 , A01N25/34 , A01N31/44
CPC分类号： A01N43/40
摘要： The invention comprises a composition of matter containing a matrix, a plasticizer and pyriproxifen for controlling fleas.
摘要翻译：本发明包括含有基质的物质组合物，增塑剂和用于控制跳蚤的吡哆酮。

65. 发明授权

US5632999A Sustained release pyriproxifen compositions for parasite control 失效
标题翻译：用于寄生虫控制的持续释放的艾曲瑞芬组合物
公开(公告)号：US5632999A
公开(公告)日：1997-05-27
申请号：US108909
申请日：1993-08-18
申请人： Thomas A. Miller
发明人： Thomas A. Miller
IPC分类号： A01K13/00 , A01K27/00 , A01N37/52 , A01N43/40 , A01N47/12 , A01N53/02 , A61K9/00 , A01N25/34
CPC分类号： A01N43/40
摘要： The invention comprises a method of controlling fleas which includes continuously administering to the haircoat of a homeothermic animal an ovicidally effective amount of 2-(1-methyl-2-(4-phenoxyphenoxy)ethoxy)pyridine (pyriproxifen) from a sustained release matrix at a rate of 0.1 mcg/kg/day to 100 mcg/kg/day. The method may also include the use of additional ingredients such as insecticides, plasticizers, lubricants and antioxidants in a sustained release matrix.
摘要翻译：本发明包括一种控制跳蚤的方法，其包括向持续释放基质中的持续释放基质中持续施用有效量的2-（1-甲基-2-（4-苯氧基苯氧基）乙氧基）吡啶（吡氯西泮）速率为0.1mcg / kg /天至100mcg / kg /天。该方法还可以包括在持续释放基质中使用附加成分例如杀虫剂，增塑剂，润滑剂和抗氧化剂。

66. 发明申请

US20200263672A1 Frozen Water Energy Generator and Method of Generating Same 审中-公开
公开(公告)号：US20200263672A1
公开(公告)日：2020-08-20
申请号：US16277600
申请日：2019-02-15
申请人： Ethan Q. Miller , Thomas A. Miller
发明人： Ethan Q. Miller , Thomas A. Miller
IPC分类号： F03G7/06 , C09K3/18
摘要： An energy generation device is disclosed which includes a reservoir adapted to receive a supply of water, a spring proximate the reservoir, a supply of calcium chloride, a drive shaft connected to the spring, an electric generator connected to the drive shaft, and a processor, the processor adapted to release the supply of calcium chloride when the supply of water in the reservoir is frozen.

67. 发明申请

US20160326156A1 THIAZOLE-SUBSTITUTED AMINOHETEROARYLS AS SPLEEN TYROSINE KINASE INHIBITORS 有权
标题翻译：噻唑替代氨基酸作为分离型酪氨酸激酶抑制剂
公开(公告)号：US20160326156A1
公开(公告)日：2016-11-10
申请号：US15105316
申请日：2014-12-18
申请人： Thomas A. MILLER , Alessia PETROCCHI , Eric T. ROMEO , Dilrukshi VITHARANA , Solomon D. KATTAR , Alan B. NORTHRUP , Michael D. ALTMAN , Neville J. ANTHONY , MERCK SHARP & DOHME CORP.
发明人： Thomas A. Miller , Alessia Petrocchi , Eric T. Romeo , Dilrukshi Vitharana , Solomon D. Kattar , Alan B. Northrup , Michael D. Altman , Neville J. Anthony
IPC分类号： C07D417/12 , C07D495/04 , A61K31/437 , C07D471/04 , A61K31/444 , C07D491/048 , A61K31/517 , A61K31/519
CPC分类号： C07D417/12 , A61K31/437 , A61K31/444 , A61K31/517 , A61K31/519 , C07D413/12 , C07D417/14 , C07D471/04 , C07D491/048 , C07D495/04
摘要： The invention provides certain thiazole-substituted aminoheteroaryl compounds of the Formula (I) (I), or pharmaceutically acceptable salts thereof, wherein ring R1, R2, R3, R4, ring A, and the subscripts n1, n2, and r are as defined herein. The invention also provides pharmaceutical compositions comprising such compounds, and methods of using the compounds for treating diseases or conditions mediated by Spleen Tyrosine Kinase (Syk).
摘要翻译：本发明提供了式（I）（I）的某些噻唑取代的氨基杂芳基化合物或其药学上可接受的盐，其中R 1，R 2，R 3，R 4，环A和下标n 1，n 2和r如上定义这里。本发明还提供包含这些化合物的药物组合物，以及使用该化合物治疗由脾脏酪氨酸激酶（Syk）介导的疾病或病症的方法。

68. 发明授权

US08101663B2 Polymorphs of suberoylanilide hydroxamic acid 有权
标题翻译：辛二酰苯胺异羟肟酸的多晶型物
公开(公告)号：US08101663B2
公开(公告)日：2012-01-24
申请号：US12653073
申请日：2009-12-07
申请人： Thomas A. Miller , Victoria M. Richon
发明人： Thomas A. Miller , Victoria M. Richon
IPC分类号： A61K31/165 , C07C259/04
CPC分类号： A61K31/19 , A61K9/0019 , A61K9/1652 , A61K9/4866 , A61K31/13 , A61K31/165 , A61K31/44 , A61K47/12 , A61K47/38 , C07B2200/13 , C07C259/06
摘要： The present invention provides methods of selectively inducing terminal differentiation, cell growth arrest and/or apoptosis of neoplastic cells, and/or inhibiting histone deacetylase (HDAC) by administration of pharmaceutical compositions comprising potent HDAC inhibitors. The oral bioavailability of the active compounds in the pharmaceutical compositions of the present invention is surprisingly high. Moreover, the pharmaceutical compositions unexpectedly give rise to high, therapeutically effective blood levels of the active compounds over an extended period of time. The present invention further provides a safe, daily dosing regimen of these pharmaceutical compositions, which is easy to follow, and which results in a therapeutically effective amount of the HDAC inhibitors in vivo. The present invention also provides a novel Form I polymorph of SAHA, characterized by a unique X-ray diffraction pattern and Differential Scanning Calorimetry profile, as well a unique crystalline structure.
摘要翻译：本发明提供了通过施用包含有效的HDAC抑制剂的药物组合物选择性诱导肿瘤细胞的终末分化，细胞生长停滞和/或细胞凋亡和/或抑制组蛋白脱乙酰酶（HDAC）的方法。本发明的药物组合物中活性化合物的口服生物利用度令人惊奇的高。此外，药物组合物在长时间内意外地引起活性化合物的高，治疗有效的血液水平。本发明进一步提供这些药物组合物的安全的每日给药方案，其易于遵循，并且其在体内导致治疗有效量的HDAC抑制剂。本发明还提供了SAHA的新型I型多晶型物，其特征在于独特的X射线衍射图和差示扫描量热法谱，以及独特的晶体结构。

69. 发明申请

US20100210729A1 Methods of inducing terminal differentiation 有权
标题翻译：诱导终末分化的方法
公开(公告)号：US20100210729A1
公开(公告)日：2010-08-19
申请号：US12799368
申请日：2010-04-23
申请人： Victoria M. Richon , Judy H. Chiao , William Kevin Kelly , Thomas A. Miller
发明人： Victoria M. Richon , Judy H. Chiao , William Kevin Kelly , Thomas A. Miller
IPC分类号： A61K31/195 , A61P35/00
CPC分类号： A61K9/4866 , A61K9/0019 , A61K9/1652 , A61K31/13 , A61K31/164 , A61K31/165 , A61K31/19 , A61K31/44 , A61K38/12 , A61K47/12 , A61K47/38
摘要： The present invention provides methods of selectively inducing terminal differentiation, cell growth arrest and/or apoptosis of neoplastic cells, and/or inhibiting histone deacetylase (HDAC) by administration of pharmaceutical compositions comprising potent HDAC inhibitors. The oral bioavailability of the active compounds in the pharmaceutical compositions of the present invention is surprisingly high. Moreover, the pharmaceutical compositions unexpectedly give rise to high, therapeutically effective blood levels of the active compounds over an extended period of time. The present invention further provides a safe, daily dosing regimen of these pharmaceutical compositions, which is easy to follow, and which results in a therapeutically effective amount of the HDAC inhibitors in vivo.
摘要翻译：本发明提供了通过施用包含有效的HDAC抑制剂的药物组合物选择性诱导肿瘤细胞的终末分化，细胞生长停滞和/或细胞凋亡和/或抑制组蛋白脱乙酰酶（HDAC）的方法。本发明的药物组合物中活性化合物的口服生物利用度令人惊奇的高。此外，药物组合物在长时间内意外地引起活性化合物的高，治疗有效的血液水平。本发明进一步提供这些药物组合物的安全的每日给药方案，其易于遵循，并且其在体内导致治疗有效量的HDAC抑制剂。

70. 发明申请

US20090156825A1 Fluorescent compounds that bind to histone deacetylase 审中-公开
标题翻译：结合组蛋白脱乙酰酶的荧光化合物
公开(公告)号：US20090156825A1
公开(公告)日：2009-06-18
申请号：US12313799
申请日：2008-11-25
申请人： Richard W. Heidebrecht, JR. , Astrid M. Kral , Thomas A. Miller
发明人： Richard W. Heidebrecht, JR. , Astrid M. Kral , Thomas A. Miller
IPC分类号： C07D213/78
CPC分类号： C07D213/75 , C07D311/90
摘要： The present invention relates to a novel class of fluorescent compounds that bind to histone deacetylases. The fluorescent compounds can be used to determine binding association and dissociation rates of histone deacetylase inhibitors via fluorescence polarization.
摘要翻译：本发明涉及结合组蛋白脱乙酰酶的新型荧光化合物。荧光化合物可用于通过荧光偏振来测定组蛋白脱乙酰酶抑制剂的结合关联和解离速率。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式